Home / Health / Pharma Funding Clouds FDA Advisory Panels
Pharma Funding Clouds FDA Advisory Panels
21 Oct
Summary
- Nearly 40% of FDA meetings had patient reps with industry ties.
- One in 10 drug review meetings featured pharma-affiliated reps.
- These connections were often undisclosed to the public.
A decade-long investigation has uncovered potential conflicts of interest within the U.S. Food and Drug Administration's advisory committees. Researchers found that nearly 40% of these crucial meetings involved patient or consumer representatives who had undisclosed ties to advocacy groups receiving funding from pharmaceutical companies.
Specifically, the study, spanning from 2013 to 2022, indicated that one in ten drug review meetings included a representative affiliated with a company-supported organization. Certain advisory committees, such as those for heart, kidney, and nervous system drugs, showed a higher prevalence of these industry-linked representatives, sometimes in over half of their meetings.
This raises serious questions about whether industry funding influences the recommendations made by these patient and consumer representatives. While not always a direct legal conflict, these relationships could create an appearance of a lack of impartiality, prompting calls for increased FDA oversight.
